|
| Thursday, 22 October 2015, 21:26 HKT/SGT | |
| |
|
|
|
United Kingdom, Oct 22, 2015 - (ACN Newswire) - China Regenerative Medicine International Ltd ("CRMI", HK:8158) is pleased to announce that it has jointly entered into a memorandum of understanding ("MOU"), being on the State Visit to the United Kingdom by President Xi Jinping of the PRC, to establish the "The CCBI-CRMI Technology Centre at the University of Oxford" with the University of Oxford and CCB International (Holdings) Ltd ("CCBI", a wholly-owned subsidiary of China Construction Bank Corporation) on 21 October. This is also one of the cooperation achievements for life sciences realized during the State Visit to the United Kingdom by President Xi.
Early in 2014, CRMI and the University of Oxford established the first CRMI regenerative medicine industry R&D Centre (the "Centre"), focusing on major unmet clinical needs, including but not limited to diabetes, cancer, neural degeneration and organ repair using stem cell therapy. According to the MOU, CCBI will provide GBP1.5 million of project funding to the Centre to accelerate research and its translation into treatments, and improve the operating and training capability of this Centre. The three parties, CCBI, CRMI and the University of Oxford, will cooperate to establish a strategic platform for the translation and commercialisation of biomedical research particularly in regenerative medicine. For this purpose, CCBI will provide assistance in the capital market of up to RMB60 billion to support translation and industrialisation of cutting edge research outcomes and promising projects. The new tripartite cooperation, with CCBI's participation, will ensure adequate funding for the industrialisation of R&D results for accelerating its R&D capabilities to enhance the strength of the market.
"The CCBI-CRMI Technology Centre at the University of Oxford" is part of the Oxford Institute of Biomedical Engineering (IBME), directed by Professor Zhanfeng Cui, who is the Donald Pollock Professor of Chemical Engineering at Oxford and a Fellow of the Royal Academy of Engineering. CRMI is the third enterprise to set up such a research and development technology centre that is sponsored by enterprise and undertaking research at the University of Oxford. IBME is part of the Department of Engineering Science, which hosts all three Technology Centres (Rolls-Royce and Invensys support the other two centres).
Mr. Zhengkang Shao, CEO of CRMI, expressed: "Being an innovative high-tech enterprise, CRMI always takes research and development of technology as the foundation for corporate development. For years, we have relentlessly invested enormous funds in scientific research. The cooperation with the University of Oxford not only constructs an international R&D network for China Regenerative Medicine International Limited, but also provides training opportunities to scientific researchers in China. Meanwhile, the cooperation is a bridge for scientific exchanges between China and the UK, becoming a new momentum for the development in the course of human life health."
Professor Zhanfeng Cui, FREng, the Director of the Centre stated: "The UK has always occupied a leading position in the field of stem cell research. We are always keen to translate the leading scientific research into clinical applications. While this time, the cooperation among CRMI, CCBI and the University of Oxford provide a good opportunity to combine the leading position in research and development at the University of Oxford, the industrialisation and commercialisation platforms in CRMI, the financial strength of CCBI, and to create a thrust for translational and regenerative medicine. The outcome will benefit both the UK and China.
Topic: Press release summary
Sectors: Daily News, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors
Feb 6, 2026 15:55 HKT/SGT
|
|
|
Muyuan Foods Makes Hong Kong Debut Today: Strong Cornerstone Investor Backing Fuels Rapid Earnings Growth, Embarking on New Journey of Internationalization
Feb 6, 2026 15:40 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025
Feb 6, 2026 13:13 HKT/SGT
|
|
|
Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market
Friday, February 6, 2026 12:34:00 PM
|
|
|
Eternal Beauty Holdings Limited and Lane Crawford Debut Landmark Fragrance, Further Expanding Footprint in High-Margin Niche Fragrance Market
Feb 6, 2026 12:21 HKT/SGT
|
|
|
Establishment of the World's First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony's High-Performance Products
Friday, February 6, 2026 10:50:00 AM
|
|
|
|
|
More Press release >> |
|
|
|
